GLP-1 RAs are known to delay gastric emptying, raising concerns about regurgitation, aspiration, and airway compromise during ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

With the rising popularity of glucagon-like peptide-1 agents for treating obesity, many bariatric surgery programs across the ...

Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery- Observed weight loss was 17% at 28 days, a 25% ...

The GLP-1 and related drug sector has generated tens of billions of ... PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor ...

Despite the FDA approval of several GLP-1 drugs to aid in weight loss, 6 insufficient production to meet the high demand for ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

The annual meeting of the American College of Gastroenterology was held from Oct. 25 to 30 in Philadelphia and attracted ...

The oral presentation “Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves ... patients with adequately controlled T2D on at least one glucose lowering agent (GLA). Fractyl ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 programPivotal Phase 3 trials designed to leverage the ...